Prophylaxis of sudden cardiac death in chronic Chagas' disease

Bestetti, Reinaldo B.; Cardinalli-Neto, Augusto

doi:10.1016/j.ijcard.2007.12.128

Cited by 3 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There may be changes in heart rate, especially bradycardia, by alterations in the autonomous innervation. Sudden death is an occasional complication in patients with severe underlying cardiac involvement, including ventricular aneurysms, which is a characteristic finding in cardiac Chagas (Bestetti and Cardinalli-Neto, 2009;Marin-Neto and Rassi, 2009;Rassi et al, 2009a;Rassi and Rassi, 2009). …”

Section: Clinical Aspects Of Chagas Diseasementioning

confidence: 99%

Chagas disease: Present status of pathogenic mechanisms and chemotherapy

et al. 2010

View full text Add to dashboard Cite

There are approximately 7.8 million people in Latin America, including Chile, who suffer from Chagas disease and another 28 million who are at risk of contracting it. Chagas is caused by the flagellate protozoan Trypanosoma cruzi. It is a chronic disease, where 20%-30% of infected individuals develop severe cardiopathy, with heart failure and potentially fatal arrhythmias. Currently, Chagas disease treatment is more effective in the acute phase, but does not always produce complete parasite eradication during indeterminate and chronic phases. At present, only nifurtimox or benznidazole have been proven to be superior to new drugs being tested. Therefore, it is necessary to find alternative approaches to treatment of chronic Chagas. The current treatment may be rendered more effective by increasing the activity of anti-Chagasic drugs or by modifying the host's immune response. We have previously shown that glutathione synthesis inhibition increases nifurtimox and benznidazole activity. In addition, there is increasing evidence that cyclooxygenase inhibitors present an important effect on T. cruzi infection. Therefore, we found that aspirin reduced the intracellular infection in RAW 264.7 cells and, decreased myocarditis extension and mortality rates in mice. However, the long-term benefit of prostaglandin inhibition for Chagasic patients is still unknown.

show abstract

Section: Clinical Aspects Of Chagas Diseasementioning

confidence: 99%

Chagas disease: Present status of pathogenic mechanisms and chemotherapy

et al. 2010

View full text Add to dashboard Cite

show abstract

“…In this same issue, Bestetti [1] underlines its relapsing and refractory nature to conventional antiarrhythmic treatment, which potentially requires non-pharmacologic preventive therapies, among which thoracic sympathectomy may have a role.…”

mentioning

confidence: 99%

“…Although the relevance of resting heart rate (HR) as a prognostic factor and its potential therapeutic objective is not yet definitely established, several epidemiologic studies have shown that HR is an independent factor of cardiovascular and all-cause mortality in patients with coronary artery heart disease [1,2]. Nevertheless, it is still unclear whether HR is itself the cause or there is merely an association between HR…”

mentioning

confidence: 99%